Neuralstem posts bigger loss

Neuralstem, of Germantown, a biotechnology company that produces stem-cell treatments for central nervous system diseases and conditions, reported a bigger loss for 2014 than in 2013. Neuralstem posted a net loss of $22.6 million, or 26 cents per share, compared with $19.8 million and 27 cents in 2013. “Neuralstem has progressed into a clinical development ...

Leave a Reply

Your email address will not be published. Required fields are marked *